Verastem Inc (VSTM)
Verastem, Inc. is a development-stage biopharmaceutical company focused on researching, developing, and commercializing cancer treatments in the United States. The company’s pipeline includes avutometinib, an orally administered dual RAF/MEK inhibitor designed to target the RAS/MAPK pathway, and defactinib, an oral inhibitor of FAK and proline-rich tyrosine kinase being studied in solid tumors. Verastem is advancing these candidates through several clinical programs, including RAMP 301, RAMP 201, FRAME, and RAMP 205, with studies covering recurrent low-grade serous ovarian cancer, KRAS-mutant cancers, and other oncology settings. The company also has licensing and collaboration arrangements with Chugai Pharmaceutical, Pfizer, Amgen, and GenFleet Therapeutics related to the development and potential commercialization of its programs. Founded in 2010, Verastem is headquartered in Needham, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VSTM
|
$6.72
|
16.0% Upside
|
Fair
|
$15
|
158.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-2.6x
|
6.2x
|
10.3x
|
505.3 M
|
412.6 M
|
14.5%
|
80.1%
|
-7.5
|
—
|
77.8%
|
